AVROBIO, Inc. to Present at Chardan's 2nd Annual Genetic Medicines Conference
04 oct. 2018 16h01 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare...
AVROBIO Receives No Objection to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher Disease
01 oct. 2018 07h01 HE
|
AVROBIO, Inc.
Company plans to initiate Phase 1/2 clinical trial in patients with Gaucher disease in 2019 AVROBIO continues to advance its pipeline of gene therapies for lysosomal storage disorders CAMBRIDGE,...
AVROBIO Announces Updated Clinical Data for AVR-RD-01 Gene Therapy in Fabry Disease
01 oct. 2018 07h00 HE
|
AVROBIO, Inc.
First two patients in Phase 1 study continue to demonstrate AGA enzyme activity above the diagnostic range for classic Fabry disease 18 months and six months after receiving AVR-RD-01, respectively;...
AVROBIO, Inc. to Present at Upcoming Investor Conferences
28 août 2018 08h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative...
AVROBIO, Inc. to Present at the 2018 Wedbush PacGrow Healthcare Conference
08 août 2018 08h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative...
AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors
27 juin 2018 08h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical stage gene therapy company focused on developing potentially curative lentiviral-based gene...
AVROBIO, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Option
25 juin 2018 16h30 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo...
AVROBIO, Inc. Announces Pricing of Initial Public Offering
20 juin 2018 20h42 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., June 20, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based...